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Changes in Apoptosis-Related Genes (Bcl-2, Bax) in the
Urethras of Old Female Rats Following Estrogen Replace-
ment
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Division of Urology, Department of Surgery, School of Medicine, Tottori University Faculty of
Medicine, Yonago 683-8504 Japan
Following estrogen replacement in old female rats, changes in apoptosis-related genes
(Bcl-2, Bax) in the urethra were investigated by immunohistochemical and RT-PCR
analysis.  A total of 40 old (16-month-old) female Wistar rats were divided into the following
5 groups:  normal controls; rats replaced with low-dose estradiol (E2) for 2 and 4 weeks,
respectively; and rats replaced with high-dose E2 for 2 and 4 weeks, respectively.  After
treatment, the urethras were removed, weighed and stained with hematoxylin and eosin,
and then immunohistochemical stainings of Bcl-2 and Bax were performed.  In addition,
the expressions of the apoptosis-related genes bcl-2 and bax were investigated by PCR
analysis, and then evaluated by computerized quantification.  In the E2-replaced rats, the
immunostained urethras showed little immunoreactivity against the Bcl-2 protein, and in
the control rats, no reactivity was seen.  In contrast, the control rats showed immunoreac-
tivity against the Bax protein, whereas the E2-replaced rats showed little reactivity.  Upon
mRNA analysis, the expression of bcl-2 mRNA was uprisen in rats in the high-dose E2 for
4 weeks group as compared with the controls, but the expression of bax mRNA was sup-
pressed in the E2-replaced rats as compared with the controls.  As these results suggest,
estrogen replacement up-regulated the expression of bcl-2 mRNA and down-regulated
the expression of bax mRNA, which might suppress the apoptic action:  these changes
might alter lower urinary tract findings.
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During menopause, the drop in serum levels of es-
trogen causes metabolic and atrophic alterations in
many organs (Versi, 1990).  Postmenopause uro-
genital atrophy disorder is characterized by dysuria,
urinary urgency, pollakisuria and urinary inconti-
nence (Suguita et al., 2000).
It is known that the urethra, like the vagina, is
affected by estrogen, and that hypoestrogenism at
menopause results in urogenital atrophy in all wo-
men, regardless of race, nationality or socioecono-
mic status.  With progressing estrogen deficiency
and advancing age, the urethral epithelium becomes
thinner, and loses its vascularity, elasticity and re-
gulation (Bachmann, 1998).  In addition, estrogen
depletion causes atrophic urethritis, and sometimes
accounts for urinary incontinence (Elia and Bergman,
1993).  Bhatia et al. (1989) reported that estrogen
therapy could improve the proliferation and growth
of the urethral mucosa, and that it could have a posi-
tive effect on urethral elasticity.  In another study,
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cytological examination revealed that estrogen
treatment for 3 weeks induced proliferation of the
atrophic urethral mucosa in postmenopausal wo-
men suffering from urinary incontinence (Ulmsten
and Stormby, 1987).
Recent studies have indicated that estrogen
regulates cell survival and cell death factors.  In
breast cancer cells (Teixeira et al., 1995; Kandouz
et al., 1996; Huang et al., 1997), the expression of
bcl-2 and other members of the bcl-2 family (bax,
bad and bcl-x), by which estrogen regulates, has
been shown to inhibit apoptosis.  In brain cells
(Dubal et al., 1999), estrogen prevented the injury-
induced down regulation of bcl-2 expression.
In the present study, following estrogen re-
placement therapy, we investigated the changes in
apoptosis-related genes (Bcl-2, Bax) on the urethras
of old female rats.
Materials and Methods
Animals
The animal experiment was performed at Labora-
tory Animal Center of Tottori University, in accord-
ance with the guidelines of the University.  Estro-
gen replacement was performed according to
Furuta et al. (2002).  Female Wistar rats (Shimizu,
Kyoto, Japan) were divided into 5 groups:  each
contained 8 animals.  A silastic tube (inside dia-
meter = 1.5 mm, outside diameter = 2.5 mm, length
= 30 mm) (Kaneka Medix, Osaka, Japan) contain-
ing sesami oil (Kadoya, Tokyo, Japan) was sub-
cutaneously planted into each rat at the age of 16
months.  Ovariectomy was not performed in any
groups.  No additional treatment was performed in
the control group (Group I). Plain sesami oil was
replaced with the one containing 20 µg/mL of estra-
diol (E2, Sigma, St. Louis, MO), and placed for 2
weeks (Group II) or 4 weeks (Group III), respec-
tively.  The higher dose of E2 at 200 µg/mL was ad-
ministered for 2 weeks (Group IV) or 4 weeks
(Group V), respectively.
Serum levels of estradiol
The serum E2 concentrations were assessed by
radioimmunoassay using a kit from Nihon DPC
(Tokyo).  In the control group, assay was performed
on the 14th day after the operation, and in the E2-
replaced groups, 2 weeks (groups II and IV) or 4
weeks (groups III and V) after hormone replace-
ment.
Histological examination of the rat urethra
After replacement therapy, the animals were all
anesthetized by inhalation of diethyl ether and then
weighed.  In the control group (group I), this proce-
dure was performed on the 14th day after the opera-
tion.  The urethras were removed and weighed on a
Mettler Basbal scale (Delta Range, Tokyo).  After
the procedure, all rats were sacrificed.  Four ure-
thras in each group were fixed in 10% formalin and
embedded in paraffin, and the remaining 4 were
frozen in liquid nitrogen.  Each paraffin block was
serially sectioned and routinely stained with hemat-
oxylin and eosin (HE).  For immunohistochemical
staining of Bcl-2 and Bax, we used the monoclonal
antibodies against Bcl-2 (Santa Cruz Biotechnology,
Santa Cruz, CA) and Bax (Santa Cruz Biotechnology).
The serial sections were also immunohistochemi-
cally stained with a Histfine Simple Stain Rat MAX
PO (MULTI) kit (Nichirei, Tokyo) according to the
manufacturer’s instructions (UIP method).
Reverse transcription-PCR analysis
The remaining 4 urethras per group were frozen in
liquid nitrogen.  The total RNA was extracted from
the dissected tissues using TRIzol reagent
(Invitrogen, Carlsbad, CA) according to the manu-
facturer’s instructions, treated with deoxyribonu-
clease [reverse transcription (RT) grade] (Nippon
Gene, Tokyo) and then quantified spectrophoto-
metrically.  In this experiment, 5 µg of total RNA
was reverse-transcribed in a 20 µL reaction volume.
RT was carried out with Moloney murine leukemia
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Table 1.  Body weight, urethral weight and serum E2 levels
Body weight Urethral weight Serum E2 levels
(g) (mg) (pg/mL)
Group I 353 ± 37.0 23.0 ± 4.6 7.3 ± 2.5
Group II 358 ± 28.0 30.7 ± 4.8 25.0 ± 4.8
Group III 339 ± 24.3 30.4 ± 6.8 29.4 ± 10.7
Group IV 332 ± 34.4 29.8 ± 2.8 258.1 ± 55.0
Group V 340 ± 23.2 33.7 ± 6.4 213.6 ± 67.3
Data are expressed as mean ± SD.
Statitical analysis by Student’s t-test.
E2, estradiol.
  * Significant differences; P < 0.05.
** Significant differences; P < 0.01.
virus reverse transcriptase (Roche Molecular Sys-
tems, Branchburg, NJ), and PCR was performed us-
ing AmpliTag gold DNA polymerase (Roche Mo-
lecular Systems).  The primers used for bcl-2 were
5'-CACCCCTGGCATCTTCTCCTT-3' (sense) and
5'-AGCGTCTTCAGAGACAGCCAG-3' (antisense)
(Genbank accession number U34964, 519 bp), and
these for bax were 5'-CACCAGCTCTGAACAGAT
CATGA-3' (sense) and 5'-TCAGCCCATCTTCTT
CCAGATGGT-3' (antisense) (Genbank accession
number RRU 49729, 540 bp) (Ananth et al., 2001).
The PCR cycles consisted of denaturation at 94˚C
for 30 s, annealing at 68˚C for 30 s and extension at
72˚C for 1 min for 26 cycles (bcl-2); and denatura-
tion at 94˚C for 30 s, annealing 62˚C for 30 s and
extension at 72˚C for 1 min for 26 cycles (bax).  As
a control, a 285-bp DNA of rat β-actin was also
amplified using 5'-TCATGAAGT GTGACGTTG
ACATCCGT-3' (sense) and 5'-CCTAGAAGC
ATTTGCGGTGCAGGATG-3' (antisense) primers
(Ananth et al., 2001).  The temperature cycling
conditions were as follows:  10 min at 94˚C 18
cycles of (94˚C for 30 s, 65˚C for 30 s, 72˚C for 30
s) and a final extension at 72˚C for 30 s.  The PCR
product was size separated by electrophoresis on a
2% cyber green-containing agarose gel, and
photographed.  For quantification, photographs
showing the PCR products were scanned and
analyzed using Densitograph version 4.0 software
(ATTO, Tokyo).  On each sample, signal strength
was normalized by that of β-actin.
Statistical analysis
All data was analyzed by Student’s t-test.  Statis-
tical significance was defined as P < 0.05.
Results
Serum levels of estradiol
The results of serum E2 levels are recorded in Table
1.  The serum E2 levels in the replaced groups were
significantly higher than those in the control group.
Compared in terms of the E2 dose, the serum E2
levels were about 10 times higher in the high-dose
groups (groups IV and V) than in the low-dose
groups (groups II and III) (Table 1).
Body and urethral weight
There were no significant differences among
groups in body weight.  However, urethral weight
was significantly heavier in the E2-replaced groups
than in the control group, although there were no
significant differences among the E2-replaced
groups in urethral weight (Table 1).
*
*
**
**
*
**
*
*
**
**
**
*
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Histological changes in the rat
urethras
There were no significant differences
between the control and E2-replaced
rats in the HE stains of the urethra.
Figures 1a and b show representative
light microscopic photographs of the
urethras  immunostained by the
antibody against Bcl-2:  Fig. 1a for the
control rats, and Fig. 1b for the group V
rats replaced with high-dose E2 for 4
weeks.  Bcl-2 was not detected clearly
in the urethra of the control rats.
However, in the mucosal region of the
urethra of the E2-replaced rats, weak
immunoreactivity against Bcl-2 was
detected.
Figures 2a and b show urethras
similarly stained by the antibody against Bax in the
control rats and the group V rats.  Bax was detected
strongly in the mucosal region of the urethra of the
control rats, but in the urethra of the E2-replaced
rats, weak immunoreactivity against Bax was de-
tected.
RT-PCR analysis of expression of bcl-2 and
bax mRNA
The expressions of bcl-2 mRNA were significantly
increased in group V compared with
the control group.  In the other E2-
replaced groups, there were no signif-
icant differences in the expressions of
bcl-2 mRNA compared with the control
group.  However, the expressions of
bax mRNA were significantly de-
creased in groups III and V compared
with the control group.  In groups II and
IV, the expressions of bax mRNA
showed no significant differences
compared with the control group.  The
bax/bcl-2 ratio was significantly lower
in groups III and V than in the control
group (Fig. 3).
Fig. 1.  Immunohistochemical stains of the rat urethras by an antibody
against Bcl-2 protein.
       a:  A control rat (× 200).
       b:  A group-V rat replaced with high-dose E2 for 4 weeks (× 200).
Fig. 2.  Immunohistochemical stains of the rat urethras by an antibody
against Bax protein.
       a:  A control rat (× 200).
       b:  A group-V rat replaced with high-dose E2 for 4 weeks (× 200).
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Discussion
Rats are fertile until approximately 15 months of
age, and thereafter their estrous cycle stops.
Several studies indicated that the E2 levels are less
than 10 pg/mL in ovariectomized female rats
(Shulman et al., 1987; Albert et al., 1991).  Other
studies have indicated that serum E2 levels of 15 pg/
mL are slightly below the mean level of E2
throughout the estrous cycle (9–27 pg/mL), or
about 1/3 of the maximum value E2 (35–52 pg/mL)
reached during the estrous cycle (Dupon and Kim,
1973; Overpeck et al., 1978).  In the present study,
the E2 levels were lower than 10 pg/mL in the
control group.  In the E2-replaced groups, the mean
serum E2 levels reached over 20 pg/mL in the low-
dose groups, and 200 pg/mL in the high-dose
groups.  Thus, this method of estrogen replacement
was adequate for studying the effect of estrogen on
the rat urethras.
Previous studies showed that estrogen deple-
tion resulted in increased body weight (Eika et al.,
1990).  In the present study, there was no significant
difference in body weight was observed among
groups.  However, the mean urethral weight of the
E2-replaced rats was significantly higher than that
of the control rats.  These results suggest that estro-
gen replacement after menopause increases urethra
weight in rats.  No previous studies have shown
changes in female rats’ urethral weight after estro-
gen replacement.  However, a few studies indicated
that estrogen replacement might raise bladder
weight as the collagen content of the bladder
increases and the bladder epithelium thickens
(Suguita et al., 2000; Eika et al., 1990).  On the
other hand, several studies have demonstrated the
presence of estrogen receptors in the human lower
urinary tract.  This provides evidence for the direct
actions of estrogens on the bladder and urethra
(Batra and Iosif, 1987; Versi, 1990).  Estrogen
therapy could improve the proliferation and growth
of the urethral mucosa (Bhatia et al., 1989), and
cause an increase in urethral collagen content and
urethral blood flow (Batra et al., 1986).  These
Fig. 3.
a:  Semiquantitative RT-PCR analysis of mRNA expres-
sion of bcl-2, bax and β-actin in rat urethras.  RT,
reverse transcription.
b:  Relative densities of bcl-2 and bax mRNA signals,
and relative bax/bcl-2 ratio.  The signals are normal-
ized with corresponding β-actin signals.  Each bar
represent the mean ± SEM.  Statistical significances
were examined in comparison to the control level ex-
pressed as 100%; significant difference; P < 0.05.
a
b
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changes in E2-replaced rats might increase the ure-
thral weight as the bladder weight.  However, the
present study did not show significant differences
in the HE staining of urethras between the control
and E2-replaced rats.  The differences in urethral
weight between the control and E2-replaced rats
was about 5 to 10 mg.  It might be difficult to detect
differences in urethral mucosa or collagen content
by HE staining.
In the present immunohistochemical staining,
immunoreactivity against Bcl-2 was not detected
clearly in the urethras of the control rats, but slight-
ly detected in the mucosal region of the urethras of
the E2-replaced rats.  However, immunoreactivity
against Bax was detected more strongly in the
mucosal region of the urethras of the control rats
than in the E2-replaced rats.
In the RT-PCR analysis, the expressions of
bcl-2 mRNA were significantly increased in group
V (high-dose E2 replaced for 4 weeks) compared
with the control group.  In the other E2-replaced
groups, the mean expressions of bcl-2 mRNA were
higher than in the control group.  However, the ex-
pressions of bax mRNA were significantly decreas-
ed in groups III (low-dose E2 replaced for 4 weeks)
and V (high-dose E2 replaced for 4 weeks) compar-
ed with the control group.  In the other E2-replaced
groups, the mean expressions of bax mRNA were
lower than in the control group.  The bax/bcl-2 ratio
was significantly lower in groups III and V than in
the control group.  The administration period for 2
weeks might have been too short to cause a differ-
ence in gene expression.  RT-PCR analysis suggest-
ed that estrogen replacement up-regulates the bcl-2
gene expression and down-regulates the bax gene
expression.  Considering the histological results,
these changes occured mainly in the mucous mem-
brane of the rat urethra.  Thus, it seems that epithe-
lium cells were estrogen dependent rather than sub-
mucosal cells.
It is known that Bcl-2 inhibits most types of
cell death, implying a common mechanism of le-
thality.  Bcl-2 is localized to intracellular sites of
oxygen-free radical generation, including mito-
chondria, endoplasmic reticula and nuclear mem-
branes.  The mechanism by which Bcl-2 exerts its
antiapoptotic effects is not fully resolved, although
it has been speculated that Bcl-2 acts as either a re-
gulator of an antioxidant pathway that prevents oxi-
dative damage, such as lipid peroxidation caused by
the generation of free radicals (Tsujimoto and
Croce, 1986; Hockenbery et al., 1993), or as a
regulator of intracellular Ca2+ compartmentaliza-
tion (Kane et al., 1993).  The antiapoptotic activity
of Bcl-2 correlates with its intracellular ratio to
another recently described protein called Bax.  Bcl-
2 heterodimerizes with Bax.  High levels of Bax
have been shown to favor apoptosis in cells sub-
jected to growth factor deprivation, whereas high
levels of Bcl-2 prolong cell survival under the same
conditions (Bafy et al., 1993).  In other studies, Bcl-
2, a cell survival factor, has been identified as an
estrogen responsive gene in reproductive tissues.
Estrogen may directly up-regulate this survival
factor through receptor-mediated interactions with
regions of the bcl-2 promotor, which contains sev-
eral putative estrogen-responsive sites, or by an in-
direct pathway.  Estrogen depletion results in a
marked decrease in bcl-2 expression, and in the
absence of estrogen, the bax/bcl-2 ratio is increas-
ed.  In this type of situation, estrogen-dependent
tissues undergo apoptosis (Teixeira et al., 1995).
In the present study, considering the changes
in apoptosis related genes (Bcl-2, Bax), estrogen
replacement might prevent apoptosis mainly in the
urethral mucosa of old female rats.  However, it is
difficult to demonstrate the reason why the im-
munoreactivity was observed mainly in the mucosa.
Further studies need to be performed to assess the
relation between the expression of apoptosis-
related genes on the female urethra and estrogen
replacement.
It appears from our study that in the mucosa of
the rat urethra, estrogen replacement up-regulates
the bcl-2 gene expression and down-regulates the
bax gene expression.  These results indicate that
estrogen replacement may prevent apoptosis in the
urethras of old female rats.
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